Clinical relevance of circulating donor-specific HLA antibodies

Current Opinion in Organ Transplantation

Volumn 15, Issue 4, 2010, Pages 462-466

  Claas, Frans H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HLA antibodies; immunological risk; rejection; transplantation

Indexed keywords

EPITOPE; HLA ANTIBODY; ANTIBODY; HLA ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; COMPLEMENT DEPENDENT CYTOTOXICITY; CORRELATION ANALYSIS; DONOR; GRAFT FAILURE; HUMAN; KIDNEY TRANSPLANTATION; REVIEW; RISK FACTOR; TREATMENT CONTRAINDICATION; BLOOD; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; ORGAN TRANSPLANTATION; RISK ASSESSMENT;

ANTIBODIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ORGAN TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS;

EID: 77955229994     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833b9c38     Document Type: Review

References (48)

1. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204:998-1000.
2. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with preexisting humoral antibodies against donor cells. Lancet 1966; 2:662-665.
3. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739.
4. Tait BD. Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol 2009; 21:573-577.
5. Gebel HM, Bray RA, Nickerson P. Pretransplant assessment of donorreactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003; 3:1488-1500.
6. Susal C, Dohler B, Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol 2009; 70:569-573.
7. Opelz G, Claas FH. Which human leukocyte antigen antibodies are really clinically relevant? Hum Immunol 2009; 70:561-562.
8. Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009; 70:584-588.
9. Aubert V, Venetz JP, Pantaleo G, Pascual M. Are all donor-specific antibodies detected by solid-phase assay before transplantation clinically relevant? Transplantation 2009; 87:1897-1898.
10. Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceaseddonor kidney allograft survival. Hum Immunol 2009; 70:589-594.
11. Gupta A, Sinnott P. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum Immunol 2009; 70:618-622.
12. Van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85:1086-1090.
13. Gebel HM, Moussa O, Eckels DD, Bray RA. Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums. Hum Immunol 2009; 70:610-617.
14. Vaidya S. Clinical importance of antihuman leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008; 85:1046-1050.
15. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum Immunol 2009; 70:574-579.
16. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86:1864-1868.
17. Eng HS, Bennett G, Bardy P, et al. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important posttransplantation monitoring tools. Hum Immunol 2009; 70:595-599.
18. Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78:190-193.
19. Bohmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4dpositive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7:117-121.
20. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9:201-209.
21. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74:1192-1194.
22. Lachmann N, Terasaki PI, Budde K, et al. Antihuman leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87:1505-1513.
23. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408-415.
24. Bartel G, Regele H, Wahrmann M, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8:2652-2660.
25. Bohmig GA, Bartel G, Regele H, Wahrmann M. Prospects and limitations of posttransplantation alloantibody detection in renal transplantation. Hum Immunol 2009; 70:640-644.
26. Marrari M, Duquesnoy RJ. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transpl Immunol 2010; 22:105-109.
27. Heinemann FM, Roth I, Rebmann V, et al. Immunoglobulin isotype-specific characterization of antihuman leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol 2007; 68:500-506.
28. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006; 6:1829-1840.
29. Ting A, Morris PJ. Successful transplantation with a positive T and B cell crossmatch due to autoreactive antibodies. Tissue Antigens 1983; 21:219-226.
30. Chapman JR, Taylor CJ, Ting A, Morris PJ. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome. Transplantation 1986; 42:608-613.
31. McCalmon RT Jr, Tardif GN, Sheehan MA, et al. IgM antibodies in renal transplantation. Clin Transplant 1997; 11:558-564.
32. Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 2009; 70:563-568.
33. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, Luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7:2809-2815.
34. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70:605-609.
35. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008; 8:41-49.
36. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4dfixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22:982-989.
37. Bohmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008; 13:411-418.
38. Arnold ML, Zacher T, Dechant M, et al. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol 2004; 65:1288-1296.
39. Arnold ML, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A noncomplement-binding anti- HLA alloantibodies in retransplant candidates. Tissue Antigens 2008; 72:60-66.
40. Stastny P, Ring S, Lu C, et al. Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum Immunol 2009; 70:600-604.
41. Claas FH, Doxiadis II. Human leukocyte antigen antibody detection and kidney allocation within Eurotransplant. Hum Immunol 2009; 70:636-639.
42. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006; 67:847-862.
43. Kosmoliaptsis V, Chaudhry AN, Sharples LD, et al. Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2009; 88:791-798.
44. Cai J, Terasaki PI, Anderson N, et al. Intact HLA not beta2m-free heavy chainspecific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88:226-230.
45. Breimer ME, Rydberg L, Jackson AM, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009; 87:549-556.
46. Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005; 17:541-545.
47. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80:1194-1197.
48. Dankers MK, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004; 77:1236-1239.